Methods of treating atypical hemolytic uremic syndrome with anti-C5 antibodies
First Claim
1. A method for treating Atypical Hemolytic Uremic Syndrome (aHUS), the method comprising administering to the subject an antibody, or antigen-binding fragment, thereof in an amount effective to treat the C5 mediated complement-associated condition, wherein the antibody, or antigen-binding fragment thereof, binds to complement component human C5, inhibits the cleavage of C5 into fragments C5a and C5b, has a serum half-life in humans of at least 40 days, and comprises:
- (i) a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
23, a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
19, a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
3, a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
4, a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
5, and a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
6; and
(ii) a variant human IgG Fc constant region that binds to human neonatal Fc receptor (FcRn), wherein the CH3 domain of the variant human Fc constant region comprises Met-429-Leu and Asn-435-Ser substitutions at residues corresponding to methionine 428 and asparagine 434 of a native human IgG Fc constant region, each in EU numbering.
2 Assignments
0 Petitions
Accused Products
Abstract
The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human.
-
Citations
7 Claims
-
1. A method for treating Atypical Hemolytic Uremic Syndrome (aHUS), the method comprising administering to the subject an antibody, or antigen-binding fragment, thereof in an amount effective to treat the C5 mediated complement-associated condition, wherein the antibody, or antigen-binding fragment thereof, binds to complement component human C5, inhibits the cleavage of C5 into fragments C5a and C5b, has a serum half-life in humans of at least 40 days, and comprises:
-
(i) a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
23, a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
19, a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
3, a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO;
4, a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO;
5, and a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO;
6; and(ii) a variant human IgG Fc constant region that binds to human neonatal Fc receptor (FcRn), wherein the CH3 domain of the variant human Fc constant region comprises Met-429-Leu and Asn-435-Ser substitutions at residues corresponding to methionine 428 and asparagine 434 of a native human IgG Fc constant region, each in EU numbering. - View Dependent Claims (2, 3, 4, 5, 6, 7)
-
Specification